| 15.05 -0.4 (-2.59%) | 04-19 14:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.67 |
1-year : | 22.43 |
| Resists | First : | 17.7 |
Second : | 19.2 |
| Pivot price | 16.79 |
|||
| Supports | First : | 15.27 |
Second : | 12.7 |
| MAs | MA(5) : | 16.11 |
MA(20) : | 16.81 |
| MA(100) : | 13.97  |
MA(250) : | 10.06 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 19 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 20.69 | Low : | 5.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EWTX ] has closed above bottom band by 12.3%. Bollinger Bands are 14.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.95 - 17.04 | 17.04 - 17.12 |
| Low: | 15.42 - 15.52 | 15.52 - 15.6 |
| Close: | 15.49 - 15.66 | 15.66 - 15.79 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Thu, 18 Apr 2024
Vontobel Holding Ltd. Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Wed, 17 Apr 2024
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 3.4% - MarketBeat
Mon, 15 Apr 2024
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of ... - InvestorsObserver
Fri, 23 Feb 2024
Edgewise Therapeutics, Inc. Is Worried About This – Should You Be Worried Too? - TipRanks.com - TipRanks
Thu, 22 Feb 2024
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Business Wire
Sun, 18 Feb 2024
Edgewise Therapeutics: Behind The Massive Rally (NASDAQ:EWTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 5,720 (K) |
| Shares Short P.Month | 5,460 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -9.85 |
| PEG Ratio | 0 |
| Price to Book value | 3.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|